http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-076016-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f7b665fb8f15d0e2b0911539d39f8a2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
| filingDate | 2010-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dac2fb3f09e2506d4618f47d65ed0cd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dc92aca39e78ff6a56fc1b6ddaa783b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4274ad7e018bee59b676e5febd2fa21e |
| publicationDate | 2011-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-076016-A1 |
| titleOfInvention | DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE |
| abstract | Claim 1: Composition comprising domperidone or a pharmaceutically acceptable salt thereof for use in the treatment or prevention in a mammal of a disease associated with an alteration of the immune response, wherein the composition is prepared for administration of a dose. Domperidone daily from 0.2 mg / kg / day to 1 mg / kg / day. Claim 5: Composition according to any previous claim, characterized in that it is prepared as an oral dosage form for administration once a day. Claim 6: Composition according to any preceding claim, characterized in that it is for use in the treatment or prevention in a dog of a disease associated with an alteration of the immune response. Claim 8: Composition according to any preceding claim, characterized in that it is for use in the treatment or prevention of a disease selected from the group of diseases associated with an alteration in cellular immunity mediated by CD4 + Th1 lymphocytes. Claim 9: Composition according to claim 8, characterized in that the disease is leishmaniosis. Claim 15: Composition according to claim 14, characterized in that it comprises both domperidone and a leishmanicidal agent such as N-methylglucamine or miltephosin antimonate or in a single dosage form or in separate dosage forms. Claim 17: Composition according to claim 16, characterized in that it comprises both domperidone and a leishmaniostatic agent such as allopurinol either in a single dosage form or in separate dosage forms. |
| priorityDate | 2009-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.